The Next 10 Years To Serve As A Booster To Innovation For Human Papillomavirus Testing Market (Reaching US$ 1,130 Million)

The Human Papillomavirus Testing Market will witness a CAGR of 7.6% by reaching US$ 1,130 Million from 2025. The new-fangled healthcare electronic technologies like 3D printing, GPS tracking, and wearable biometric devices are being tested concerning clinical use. Cutting-edge technology is expected to be one of the driving forces in the healthcare industry in the subsequent decade.

Various healthcare and government insurance providers are offering reimbursement for diagnosis of chronic disorders such as cervical cancer screening. For instance, Medicare – U.S. government-funded health insurance provider, provides reimbursement to people who are of age 65 or older and some younger population with disabilities.

Moreover, for cervical cancer diagnosis, such plans cover reimbursement for one pap test every three years or a combination of pap test & HPV testing every five years. Favorable government initiatives as such are expected to drive the demand for Human Papillomavirus (HPV) testing market in the years to come.

How About Looking Through The Sample Of Human Papillomavirus Testing Market Report? https://www.persistencemarketresearch.co/samples/11737

Company Profiles 

• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Hologic Inc.
• Cepheid Inc.
• SEEGene Inc.
• Takara Bio Inc.
• DaAn Gene Co., Ltd. of Sun Yat-Sen University
• Promega Corporation
• Greiner Bio-One International GmbH (Greiner Holding AG)
• Enzo Biochem Inc.
• Norgen Biotek Corp.
• DiagCor Bioscience Inc Ltd
• Hybribio Limited
• Zytovision GmbH
• Arbor Vita Corporation
• Medical & Biological Laboratories Co., Ltd
• Fujirebio Diagnostics, Inc.
• Others.

HPV testing is gradually becoming crucial for cervical cancer screening, according to recent report published by Persistence Market Research.

The report estimates that in 2017, the global market for Human Papillomavirus testing will reach an estimated value of US$ 629.4 Mn. Improving reimbursement scenario, coupled with high sensitivity of Human Papillomavirus testing in low resource setting, is expected to drive the market’s growth.

By the end of 2025, the global market for Human Papillomavirus testing will have soared at 7.6% CAGR, bringing in more than US$ 1,100 Mn in revenues.

How About Step-By-Step Insights To Human Papillomavirus Testing Market? Look Through The “Methodology” Employed! https://www.persistencemarketresearch.co/methodology/11737

Global HPV Testing Market – Key Challenges

A key limitation for Human Papillomavirus testing is that these tests are confined to women as men undergoing HPV testing have higher risks of getting infected with genital warts. In addition to this, patients are not willing to take Human Papillomavirus tests because of lack of diagnosis options.

Over-diagnosis of Human Papillomavirus testing can cause more complications and can even risk the life of patients. Meanwhile, the global revenues from Human Papillomavirus testing are being lowered due to availability of HPV vaccines.

Preference to HPV vaccines is directly impeding the revenues arising from Human Papillomavirus testing. High cost of HPV screening test, overburdened healthcare system, low awareness on HPV prevention, and imperfections in organized screening programs are some other challenges impacting the growth of global HPV testing market.

According to the report, North America’s Human Papillomavirus testing market will be valued at nearly US$ 640 Mn, dominating the global market revenues.

Want To Keep A Tab On The Latest Findings In The Human Papillomavirus Testing Market? Purchase Our Human Papillomavirus Testing Market Report Now! https://www.persistencemarketresearch.com/checkout/11737

The demand for Human Papillomavirus testing will also be significant in Europe, Latin America and Asia-Pacific, while Middle East & Africa’s Human Papillomavirus testing revenues will attribute to less than 4% of global market value.

The report also projects that over 60% of global HPV testing revenues will be accounted by DNA-based test products. While hospitals will be largest end-users of HPV testing globally, the end-use of Human Papillomavirus testing will gain traction in diagnostic centers as well.

And, the report also reveals that close to 90% of global Human Papillomavirus testing market value throughout the forecast period will be accounted by molecular diagnostic application of Human Papillomavirus testing.

Access Trending Reports:

Polycystic Ovarian Syndrome Drugs Market – The global polycystic ovary syndrome drugs market is expected to register a CAGR of 4.6% during the forecast period 2016–2024 and is expected to expand 1.5x in terms of revenue by 2024.

Surgical Helmet System Market – The global surgical helmet systems market is projected to expand at a CAGR of 4% through 2030, to reach a value of US$ 80 Mn in 2030.

Gastric Electric Stimulators Market – Persistence Market Research (PMR) has studied the global gastric electric stimulators market for a period of 8 years, 2018–2026, offering critical insights into demand-driving factors, shaping the adoption trajectory.

About Us:-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Contact us:

Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Contact Information:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007, United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353